je.st
news
Tag: premarket
Premarket Biotech Digest: Novartis Earnings, Portola Lawsuits, Celgene's Orphan Drug
2015-07-23 11:13:42| Biotech - Topix.net
Xarelto, Eliquis and other anticoagulants that face products liability lawsuits have made deals with Portola, which is developing an antidote. One of the first anticoagulants, warfarin, was used as rat poison for 50 years before it began life as a blood thinner - and the only reason it did that was because a US Army sergeant who tried to kill himself with it was cured when treated with Vitamin K. Moral of the story- if you want to develop an anticoagulant, you better also develop its antidote, or you could bungle your way into multiple lawsuits.
Tags: drug
earnings
digest
biotech
Premarket Biotech Digest: Options Trading, Achillion Short Interest, Opdivo EU Approval
2015-07-18 14:38:03| Biotech - Topix.net
I am no options expert, but I have written covered calls occasionally to boost returns on some of my holdings. Writing covered calls can be a useful strategy with large cap biopharmas like Pfizer , Merck , Johnson & Johnson and Eli Lilly .
Tags: options
short
interest
trading
Premarket Biotech Digest: J&J Earnings, Celgene Making Deals, BTDs And FTDs
2015-07-16 07:32:43| Biotech - Topix.net
The earnings season for big pharma kicked off on Tuesday as Johnson & Johnson announced second quarter results. Q2 sales at JNJ were negatively impacted by a stronger dollar and weak medical devices sales.
Tags: making
deals
earnings
digest
Delta Air Lines, Inc. (DAL) Reports Record Net Income For Q2, But Shares Balk In Pre-Market Trading
2015-07-15 19:28:50| Apparel - Topix.net
Delta Air Lines, Inc. has announced its second quarter 2015 financial results, posting adjusted earnings per share of $1.27, surpassing market expectations of $1.23. The airliner posted quarterly revenues of $10.71 billion, also beating market estimates of $10.63 billion, with growth of 0.8% year-over-year.
Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results
2015-07-13 18:14:55| Biotech - Topix.net
Gilead Sciences shares have once again seen a pullback in the last three weeks. Since June 24th, the stock is down nearly 7%, presenting another good opportunity to buy.
Tags: results
reports
novo
digest
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] next »